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Summary 
Human herpesvirus 6 (HHV-6), a T-lymphotropic human herpesvirus, is a potentially immuno- 
suppressive agent that has been suggested to play a role as a cofactor in the natural history of 
human immunodeficiency virus (HIV) infection. We studied the interactions between HHV-6 
and 3"/8 T  lymphocytes, a subset of T  cells involved in the protective immune response against 
specific microorganisms. Polyclonal 3'/8 T  cell populations, purified from the peripheral blood 
of healthy adults and activated in vitro with phytohemagglutinin, were exposed to HHV-6, 
strain GS (subgroup A), at the approximate multiplicity of infection (MOI) of 1. Signs of virus 
replication were detected as early as 72 h after infection, as documented by immunofluorescence, 
electron microscopy, and transmission of extracellular virus. Progression of the infection was 
associated with the appearance of typical cytomorphological changes and, eventually, massive 
cell death. In contrast,  no signs of infection or cytopathic effects were detected after exposure 
of 3'/8 T  lymphocytes to HHV-7,  a CD4 + T-lymphotropic virus closely related to HHV-6. 
Polyclonal 3'/8 T cells displayed cytolytic activity against both autologous and heterologous target 
cells infected with HHV-6  and maintained this activity for at least 72 h  after infection with 
HHV-6,  despite the high MOI used. As previously documented in mature CD8 + oe/3 T cells 
and natural killer cells, HHV-6 infection induced 3`/8 T  lymphocytes to express de novo CD4 
messenger RNA and protein, as detected by reverse transcriptase-polymerase chain reaction and 
fluorocytometry,  respectively.  Whereas  purified  CD4-  3'/8  T  cell  populations were  per  se 
refractory to HIV infection, they became susceptible to productive infection by HIV-1,  strain 
IIIB, after induction of CD4 expression by HHV-6. These results demonstrate that 3`/8 T cells 
can be directly targeted and killed by a herpesvirus and may have implications for the potential 
role of HHV-6  in AIDS. 
,•ter 
the identification of the TCR,  the main antigen- 
recognition structure on the surface membrane of T lym- 
phocytes, two distinct lineages of T  cells have been defined, 
i.e., oe/~ and 3'/8 T  cells, based on the selective expression 
of different TCR heterodimers associated with CD3 (1). The 
oL, 8, %  and 8 genes have a similar genomic organization, 
despite a more limited combinatorial potential for 3` and 8, 
and undergo a similar somatic rearrangement during the pro- 
cess ofT cell differentiation, albeit differently timed (1). Our 
knowledge of the physiology and function of 3`/8 T  cells 
is still limited, but it is clear that they respond to antigens 
in a different fashion compared to o~//~ T cells. Whereas oe/~ 
T cells recognize peptide antigens combined with either class 
I or II MHC molecules, the response of 3`/8 T cells is appar- 
ently  not  restricted  by  polymorphic MHC  elements  (1). 
Moreover, unlike oe/~ T  cells,  3`/8 T  lymphocytes do not 
usually express, along with the CD3/TCR complex, the CD4 
or CD8 antigens, two membrane glycoproteins with an ac- 
cessory function in the process of antigen-mediated T  cell 
activation (1). 
The role of3`/8 T cells in the protective immune response 
against invading microorganisms has only recently started to 
be unraveled. Recent in vivo data indicate that 3'/8 T  cells 
play a unique defensive role against Listeria monocytogenes in 
mice, acting in synergy with ol/O T  cells (2,  3).  In vitro, 
3'/8 T  cells proliferate,  secrete cytokines, and display cyto- 
toxic activity in response to diff~ent antigens, including viruses 
(e.g., Herpesviridae), bacteria (e.g., Mycobacteria), and protozoa 
(e.g., Plasmodia) (1).  It is interesting, however, that 3'/8 T 
cells can also be activated in vitro by host-encoded antigens, 
such as heat-shock proteins (1). Thus, the in vivo response 
of 3'/8 T  cells to microorganisms may be, at least in part, 
secondary to the effects that the infection induces in the host, 
suggesting a possible role of 3"/8 T  cells in the regulation 
of the  immune response  and/or  in  self-reactive  immune 
phenomena. 
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photropic human herpesvirus (5) to be discovered. Despite 
its  primary  tropism  for CD4 +  T  cells,  HHV-6  is  in  fact 
an "immunotropic"  herpesvirus,  because it can also infect 
CD8 § T  cells (6), NK cells (7), and in vitro immortalized 
B  cells  (8),  as well as,  albeit nonproductively,  cells of the 
mononuclear phagocytic system (9, 10). In all these cell types, 
HHV-6 induces dramatic cytopathic changes, suggesting that 
it may act as an immunosuppressive agent in vivo. Moreover, 
a  series of positive viral interactions has been documented 
between  HHV-6  and  HIV,  the  causative  agent  of AIDS, 
leading to the hypothesis that HHV-6 may accelerate the nat- 
ural course of HIV infection in coinfected patients (11). This 
concept has been corroborated by the recent demonstration 
that HHV-6 infection is active and widespread in terminal 
AIDS patients  (12,  13). Diverse anomalies of both the cel- 
lular  and  humoral  arms  of the immune  system  have been 
reported in patients with AIDS, including 3'/6 T  cell altera- 
tions (14-16). In this study, we have investigated the suscep- 
tibility of 3'/6 T  cells to infection by HHV-6 and the inter- 
actions between HHV-6  and  HIV  in qr  T  cells. 
Materials and Methods 
Enriched y/8  T  Cell Populations.  PBMC were obtained from 
normal adult volunteers by separation  over a Ficoll-Hypaque gra- 
dient (Pharmacia,  Piscataway, NJ). To enrich 3'//~ T  cells, a mul- 
tiple rosetting procedure with goat anti-mouse IgG-coated mag- 
netic microspheres (Dynal, Oslo, Norway) was used, as previously 
described (5). Briefly, the cells were washed twice with PBS and 
incubated for 30 min at 4~  with a cocktail of mAbs directed to- 
ward CD4 (Leu3a), CD8 (Leu2a), CD14 (LeuM3), CD16 (Leullb), 
CD19 (Leu12), CD20 (Leu16), CD56 (Leu19) (Becton Dickinson 
& Co., Mountain View, CA) and TCK-ce/B (T Cell Diagnostics, 
Cambridge, MA). All the mAbs were used at a final concentration 
of 5 #g/ml. The cells were then washed repeatedly with cold PBS 
and incubated under continuous rotation at 4~  with  the im- 
munomagnetic beads at a 40:1 ratio between beads and putatively 
positive cells. After 30 min, the beads were removed with a magnet 
and the cells remaining in suspension  transferred to a new vial. 
The latter operation was performed again to remove all the residual 
beads. The cells were subsequently pelleted and incubated a second 
time for 30 min with immunomagnetic beads  at a ratio of 40:1 
between beads and 5% of the original number of putatively posi- 
tive cells. After removing the beads twice with a magnet, the cells 
were washed and cultured in RPMI medium supplemented with 
10% fetal bovine serum and I gg/ml of purified PHA (Wellcome, 
Burgwedel, Germany). 24 h later,  partially purified human IL-2 
(Boehringer Mannheim, Mannheim, Germany) was added to the 
cultures at a concentration of 10 U/ml. The enriched cell popula- 
tions were tested for purity by fluorocytometry with the mAbs 
used for selection, as well as with mAb TCR-/~I  (T Cell Diag- 
nostics).  If purity was not superior to 98%, the cells were sub- 
jected to  two  additional cycles of purification 72 h  after PHA 
stimulation and then retested for purity. If purity was again un- 
satisfactory, two additional purification cycles were performed 96 h 
after PHA stimulation. At this time, fluorocytometric analysis con- 
1 Abbreviations used in this paper: HHV-6, human herpesvirus type 6; IF, 
immunofluorescence;  MOI, multiplicity of infection; mRNA, messenger 
RNA;  RT, reverse transcfiptase. 
sistently revealed <1.0% cells positive for any of the mAbs used 
for negative selection and >98% of the cells exhibiting the TCR 
/~1 marker. 
Viruses, Infection Procedure, and Monitoring.  The HHV-6 stock, 
strain GS (4), was prepared from infected cultures of human um- 
bilical cord blood mononuclear cells, as previously described (5). 
For infection, pelleted cells were incubated with the stock virus 
at the approximate multiplicity of infection (MOI) of 1, i.e., one 
infectious dose per cell. After 1 h at 37~  the cells were washed 
with prewarmed culture medium and resuspended  in complete 
medium supplemented with 1 U/ml of IL-2. 
The HIV-1 stock, strain 11113,  was grown in the continuous cell 
line H9 (17). The cells were infected with 10  s cpm of reverse tran- 
scriptase (KT)/I@ cells for 1 h at 37~  To minimize the amount 
of residual virus from the inoculum, the cells were washed three 
times in a 15-ml volume of  culture medium. All the residual medium 
was carefully removed each time after pelleting. The infection was 
monitored by measuring the amount of HIV-1 p24 Gag protein 
in the culture supernatants using a commercial antigen capture 
ELISA test (Dupont NEN, Boston, MA). mAb OKT4a (Ortho 
Diagnostics, Raritan, NJ), previously dialyzed and sterilized by filtra- 
tion through a 0.2 gin-membrane, was used to pretreat the cells 
at 5 #g/ml and was maintained in the cultures at the same concen- 
tration thereafter. 
mAbs and Immunologic Analyses.  The mAbs used for fluorocyto- 
metric analysis included Leu4 and Leu3a conjugated with PE (Becton 
Dickinson  &  Co.),  FITC-conjugated TCR-~I  and  TCK-ot/B, 
purified',/V2 (a) (anti-V3,9) and OF1 (T Cell Diagnostics), and 13D6, 
directed toward an HHV-6 envelope protein of 120 kD (a gift of 
Dr. Bah Chandran, University of Kansas, Kansas City, KS) (18). 
FITC-conjugated goat antiserum to murine IgG (Sigma Chemical 
Co., St. Louis, MO) was used as a second-layer reagent. Because 
the BF1 mAb recognizes an epitope that is not exposed on live 
cells, labeling with this mAb was performed on fixed cells. For 
fixation, the cell pellet was incubated with 2% paraformaldehyde 
for 10 min at room temperature, washed twice with PBS, and then 
treated with 70% ethanol at -20~  for 5 min. As a positive con- 
trol,  PHA-activated CD4 + T  cells from adult peripheral blood 
were used:  >98%  were stained  by/3F1 under these conditions. 
Fluorocytometric analysis was performed on a FACScan  |  analyzer 
(Becton Dickinson & Co.). In infected cultures, dead cells were 
removed before immunofluorescence (IF) analysis by centrifuga- 
tion on a Ficoll gradient. In addition, appropriate gating was used 
to eliminate from the analysis residual dead cells and cellular de- 
bris. Controls were stained with mouse IgG1 and IgG2 irrelevant 
antibodies  conjugated with either fluorochromes. At least 10,000 
events were accumulated in each experiment. 
To evaluate the level of HHV-6 or HHV-7 infection, indirect 
IF analysis was performed on acetone-fixed cells, as described (5), 
with mAb 9A5D12 (a gift of Dr. Balachandran)  (18), directed to- 
ward an HHV-6 nuclear phosphoprotein with a molecular mass 
of 41/110  kD, but cross-reacting with an analogous protein of 
HHV-7 (19). 
slChromium-Release Assay for Cytotoxicity.  For the cytotoxicity 
studies, a standard 4-h nCr-release  test was employed, as described 
in detail elsewhere  (20).  Before labeling,  HHV-6-infected target 
cells were centrifuged over a Ficoll gradient to remove dead cells. 
After this procedure, the viability was >80%. The percent specific 
lysis was calculated  according to the following formula:  100  x 
[(test release  -  spontaneous release)/(maximal release  -  sponta- 
neous release)]. 
RT-PCR for CD4 Messenger RNA (mRNA).  For mRNA anal- 
ysis, infected 3'/6 T  cells were harvested at day 8 after exposure 
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sayed by indirect IF. Uninfected homologous cells were cultured 
in parallel and harvested at the same time. Additional controls in- 
cluded the CD4-negative B cell line Raji, as well as normal PBMC 
previously activated with PHA in vitro. The RT-PCR assay for 
CD4 was performed on total cdlular RNA as described (7). The 
primers used for amplification were: CD4.1,  5'-GCAGTC,  C~G- 
AGCTGTGGT-3'; CD4.2,  5'-GC~TCCCCACACCTCACAGG- 
3'; the probe (CD4.3) was 5'-GAACCTGGTGGTGATGAGAGC- 
CACTCAGCT-3'. 
Results 
Productive and Cytopathic Infection of "y/8  T cells by HHV- 
6~s.  Enriched populations of 3'/5 T  lymphocytes were de- 
rived from the peripheral blood of healthy adult individuals 
by repeated negative immunomaguetic sdection cycles and 
activated in vitro with PHA. The residual contamination of 
o~/B T  lymphocytes was <1%,  as assayed by fluorocytom- 
etry. Activated 3"/5 T  cells were exposed to HHV-6,  strain 
GS (the prototype of the A subgroup of HHV-6) (4),  at an 
approximate MOI of 1 (i.e.,  one infectious dose per cell). 
The infection was monitored by indirect IF, electron micros- 
copy, and transmission of released, extracellular virus to PHA- 
activated cord blood mononuclear ceUs. Signs of productive 
infection started to be detectable at day 3 after exposure to 
the virus, as demonstrated by the expression of a nuclear early- 
late viral antigen recognized by mAb 9ASD12 (Fig. 1), which 
is not detectable in calls blocked at the immediate-early/early 
stage of HHV-6 expression (21). The various steps of HHV-6 
morphogenesis (i.e., nuclear assembly of viral nucleocapsids 
[A], cytoplasmic migration of tegument-coated particles [B], 
and extracdlular release  of mature,  enveloped virions [C]) 
were documented by transmission electron microscopy (Fig. 
2). The productive nature of the infection was further con- 
firmed by transmission of ceU-free infectious supernatants to 
cultures of susceptible ceUs (data not shown). 
Starting 4-7 d  after infection, a growing proportion of 
3'/8 T cells exhibited the typical HHV-6-induced cytomor- 
phological changes, consisting of size enlargement, refractile 
appearance,  and loss of blastic shape with the acquisition of 
an evenly rounded cellular profile. Eventually, the viral cyto- 
pathic effect induced widespread cell destruction, resulting 
in the extinction of the cultures at day 10-12 after infection. 
Lysis of Autologous and Seterologous HSV.6-infected Cells 
~  Activated "y/8  T  Lymphocytes: Late Functional Impairment 
T/8 T Lymphocytes after HHV-6 Infection.  Enriched 3"/8 
T  cell populations, previously activated in vitro with PHA 
and cultured in the presence of IL-2, were assayed for their 
ability to lyse autologous or heterologous PBMC produc- 
tively infected by HHV-6~s  in vitro. A high level of specific 
lysis was observed against autologous infected target cells (Fig. 
3 A). Similar levels of activity were detected against heterol- 
ogous target cells infected with HHV-6 (data not shown), 
whereas a lower, but stiU significant activity was seen against 
the K562 cell line, a classical NK target (Fig.  3 B). In con- 
trast,  uninfected autologous PBMC  were not lysed (<3% 
specific lysis at  a 30:1  E/T  ratio). 
To investigate the effects of HHV-6 infection on the lyric 
ability of 3'/8 T  ceUs, the effector ceUs were themselves in- 
fected with HHV-6~ at an approximate MOI of 1 and sub- 
sequently tested, at various days after infection, against au- 
tologous  HHV-6-infected  targets  and  against  K562.  As 
Figure 1.  Expression  of viral anti- 
gens in 3"/~ T lymphocytes  infected 
with HHV-6, strain  GS, as assessed  by 
indirect IF with mAb 9A5D12. 
1305  Lusso et al. Figure  2.  Electron micrograph illustrating different phases of HHV-6 maturation in an infected 3'/6 T lymphocyte. Viral nucleocapsids can be seen 
within the nucleus  (A), tegument-coated immature virions inside the cytoplasm (B),  and mature virions in the extracellular space (C). 
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Figure 3.  Lysis  of autologous HHV-6-infected  PBMC (A) and uninfected  K562 (B) by 3~//~ T cell populations before and at various times after 
infection with HHV-6. A standard slCr-release assay was used. 
illustrated in Fig. 3 A, the killing ability of3'/~ T cells against 
infected targets was only minimally affected during the first 
72 h after infection, despite the high MOI used. In contrast, 
the ability to kill K562 was already reduced by "~50%  at 
day 2-3  after infection. However, a more dramatic loss  of 
cytotoxic activity was observed, against both target cell types, 
at day 4 after infection. At this time, an increasing propor- 
tion of effector cells started to express structural viral antigens, 
as detected by indirect IF. These data demonstrate that 3(/~ 
T  cells are functionally impaired by HHV-6 infection, but 
are not immediately disarmed upon contact with the virus. 
In particular, the cytotoxic activity against infected targets 
is lost only at a relatively late stage in the course of the infec- 
tion, when active virus replication is already taking place. 
Fhorocytometric Analysis of HHV-6-infected 7/~ T Cells: De 
Novo Expression of CD4.  The expression of selected surface 
membrane antigens was analyzed in 3~/~ T cells in the course 
of HHV-6 infection. As illustrated in Fig. 4, >99%  of the 
enriched 3'/8 T  cells at day 0 expressed CD3  and the 3r/5 
TCK heterodimer (mAb TCK-~I), whereas the ol/fl TCR 
heterodimer and, in particular, the TCR fl chain (mAb flF1) 
were expressed by <1% of the cells. As expected in periph- 
eral blood 3'/8 T lymphocytes, the majority of the cells ex- 
pressed V3,9.  Less than 1% of the cells expressed CD4,  an 
antigen that is rarely detected in "y/8 T lymphocytes (1) and 
that was included in the negative selection procedure for the 
purification of "~/8 T  cells. 
To elucidate the effects of HHV-6 on 3~/~ T cells, fluorocyto- 
metric analysis was performed at various days after infection. 
The level of infection was evaluated by mAb 13D6 which 
recognizes an envelope-associated  HHV-6 antigen present on 
mature virions (18). In parallel with the progressive appear- 
ance of membrane viral antigens, de novo expression of CD4 
was dramatically induced in ~//8 T  cells in the course of 
HHV-6 infection (Fig. 4). At day 9 after infection, the CD4 
antigen was expressed by >70% of the cells. The induction 
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of CD4 was a progressive phenomenon already detectable, 
albeit at very low levels, 3 d after infection. Similar patterns 
and kinetics of CD4 induction after HHV-6 infection were 
previously documented in CD8 + ct/B T ceUs (21) and NK 
cells (7).  With the exception of a moderate loss of fluores- 
cence intensity for CD3 and the "y/~ heterodimer, no sub- 
stantial alterations were observed in the expression of the 
other antigens tested, in the course of HHV-6 infection. In 
particular, the proportion of V~9 § cells remained virtually 
constant and the TCR  B chain was consistently negative 
throughout the infection period, suggesting that cell subsets 
with unusual phenotypes, e.g., 3//i T cells, were not selec- 
tively expanded in cuhure. 
To investigate whether the induction of CD4 in HHV-6- 
infected 3'/~ T calls occurred at the transcriptional level, we 
assayed the expression of CD4 mRNA at day 8 after infec- 
tion using a RT-PCK system. Uninfected homologous cells 
were used in parallel as a control. Further controls included 
PHA-activated human PBMC (>60% CD4 +) and the Raji 
B-lymphoblastoid cell line (CD4-). As illustrated in Fig. 5, 
no CD4 mKNA was detected, despite the high sensitivity 
of the PCR test, in uninfected 3'/~ T  ceils (lane 4).  How- 
ever, HHV-6 infection induced de novo expression of CD4 
mKNA in y/~ T  cells, as documented by specific hybrid- 
ization of the CD4 oligonudeotide probe to an amplified 
cDNA product exhibiting the expected size (299 bp) (lane 
5).  This result indicates that the induction of CD4 expres- 
sion in HHV-6-infected 3,//t T cells occurs at the transcrip- 
tional level. 
Induction of Susceptibility to HIV-1 in y/$ T Cells by HHV-6 
Infection.  To elucidate whether the newly induced CD4 could 
serve as a functional receptor for HIV-1 (22, 23), "y/~ T cells 
were initially infected with HHV-6 at an approximate MOI 
of 1 and, 48 h later, exposed to HIV-1, strain IIIB (17). The 
level of HIV-1 replication was evaluated by measuring the 
amount of p24 core antigen released into the culture super- DAY  0 
DAY  3 
DAY  6 
DAY  9 
FITC 
FITC 
FITC 
FITC 
13D6  /3 F1 
13D6  flF1 
13D6  ~F1 
13D6  p F1 
O 
Vy9  TCRa/3  TCRdl 
Vy9  TCR~/3  TCRdl 
Vy9 
Vy9 
TCRM~ 
TCRa/3 
TCRdl 
TCRdl 
Figure 4.  Fluorocytometric analysis of 7//~ T cells in the course of HHV-6 infection (days 0, 3, 6, 9 after infection). FITC and PE denote irrelevant 
mAbs labeled with either fluorochrome and used as controls. 
natants  at various days after infection.  Consistent with the 
lack of the CD4 receptor, 3,/~ T cells were per se refractory 
to HIV-1 infection (Table 1). In contrast,  after HHV-6 in- 
fection, they became susceptible to productive  infection by 
HIV-1, as demonstrated by the growing kinetics of extracel- 
lular p24 antigen release. Treatment of the HHV-6-infected 
cells with an HIV-blocking mAb to CD4 (OKT4a) com- 
pletely abrogated the release of HIV-1 p24 (Table 1), conclu- 
sively demonstrating that the HHV-6-induced CD4 was es- 
sential for infection  of 3'/6 T  cells by HIV-1. 
unraveled, increasing evidence indicates that these cells rep- 
resent an essential  component of the protective response against 
specific  microorganisms (1-3). In this study, we documented 
that HHV-6, a T-lymphotropic herpesvirus, can productively 
infect y//~ T  lymphocytes, inducing important phenotypic 
and cytopathic changes. Moreover, we found that 3,/~ T cells 
can recognize and kill HHV-6-infected target cells, suggesting 
that 3'/8 T cells may play a protective role against infection 
by HHV-6 in vivo. Thus, by directly attacking 3'//~ T cells, 
Discussion 
Although the role of 3,/~ T cells in the strategic organiza- 
tion of the immune system has only recently started  to be 
Table  1.  CD4-dependent  HIV-1 Infection of 7/8  T  Cells after 
Induction of CD4 by HHV-6 
HIV-1  replication (p24) 
Viruses used 
for infection  48 h  72  h  96 h  120 h 
pg/ml 
HIV-1  <1  <1  <1  <1 
HHV-6  +  HIV-1  22  40  56  171 
HHV-6  +  HIV-1  +  OKT4a  <1  <1  <1  <1 
Figure 5.  Expression of CD4 mRNA in 7/6 T cells before and after 
infection with HHV-6 as determined by KT-PCR on total RNA. Lane 
I: PHA-activated adult PBMC  (>60% CD4 +  ); lane 2: PCR reagents 
(negative control); lane 3: Raji (CD4- B cell line); lane 4: uninfected 3'/,5 
T-lymphocyte population; and lane 5: HHV-6-infected ~///; T-lymphocyte 
population at day 8 after infection. 
Infection with HIV-1, strain IIIB, was performed 48 h after infection 
with HHV-6, strain GS, at a time when de novo CD4 expression was 
already detectable. The anti-CD4 mAb (OKT4a), previously dialyzed, 
was used at 5/,g/ml and maintained at the same concentration for the 
entire experiment.  Results  of a representative  experiment  are shown. 
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and thereby establish persistent infection. Previous studies have 
elucidated that HHV-6 is an immunotropic herpesvirus that 
can infect and kill several critical elements of the immune 
system (4-10). These biological properties suggest that in- 
fection with HHV-6  may have broad immunosuppressive 
effects, although direct in vivo evidence for such action has 
not yet been provided. Nevertheless, accumulating clinical 
evidence indicates that HHV-6 may be associated  with se- 
vere pathology, such as pneumonitis, encephalitis, and bone 
marrow suppression, in patients subjected to immunosup- 
pressive regimens after bone marrow or organ transplanta- 
tion (24-26) and in patients with AIDS (13). In HIV-infected 
patients, however, HHV-6 has been suggested to play a more 
substantial pathogenetic role (11). Diverse clinical and ex- 
perimental observations indicate that HHV-6 may contribute, 
directly or indirectly, to the destruction of CD4 + T  cells, 
a pathological hallmark of AIDS, and thereby expedite the 
course of the disease. In vitro, HHV-6 can coinfect individual 
CD4 + T  cells with HIV, accelerating the kinetics of HIV 
expression and cell death (27).  This synergistic effect may 
be due to multiple mechanisms, including the transactiva- 
tion of the regulatory sequences contained in the long ter- 
minal repeat of HIV (27-29), the release of HIV-activating 
cytokines (30) and the expansion of the range of cells suscep- 
tible to HIV by inducing de novo expression of the CD4 
receptor (7, 21).  In this study, we found that 3'/8 T  cells, 
after HHV-6 infection, are induced to express CD4 on their 
surface membrane, thus becoming susceptible to productive 
infection by HIV-1. Given the potential role of HHV-6 in 
AIDS, it is tempting to speculate that this virus might con- 
tribute, directly or indirectly, to the 3'/8 T cell abnormali- 
ties that have been described in patients infected with HIV 
(14-16). Damage to 3'/8 T lymphocytes could predispose pa- 
tients to infection by specific microorganisms that these cells 
help to control, including some (e.g., Mycobacteria) that are 
an important cause of morbidity and mortality in AIDS (31). 
We found that polyclonal 3//8 T cells induce lysis of both 
autologous and heterologous target cells infected by HHV-6, 
as previously demonstrated for NK cells (20).  Unlike 3'/8 
T cells, however, polyclonal NK cells were not productively 
infected in vitro by HHV-6, despite rapid internalization of 
the virions (7). Because polyclonal NK cells efficiently recog- 
nize and kill HHV-6-infected targets, we hypothesized that 
active recognition of the target might induce resistance to 
HHV-6 infection in the NK effectors (7).  Consistent with 
this concept, productive HHV-6 infection was documented 
in  NK clones lacking the ability to  kill HHV-6-infected 
targets, but not in clones with a high lytic activity against 
infected cells. In the present study, undoned 3'/8 T cells were 
readily infected by HHV-6,  in spite of their ability to kill 
infected targets. Whether 3'/8 T and NK cells receive different 
activatory signals from infected targets or display a different 
repertoire of reactive events (e.g., cytokine secretion, mem- 
brane alterations) remains to be established.  We observed that 
3//8 T cells maintained their cytolytic activity against infected 
cells for several days after exposure to HHV-6. The subsequent 
loss of cytotoxic ability coincided with the early stages  of 
extraceUular virus production (day 4 after infection), at a time 
when the cellular DNA and protein synthesis machineries 
start to be overtaken by the herpesvirus. The lytic effect against 
K562 started to decrease even at an earlier time after infec- 
tion (day 2), suggesting that the functional impairment in- 
duced by HHV-6 in 3'/8 T cells is generalized and not specific 
for the recognition and/or killing of virus-infected cells. In 
another herpesvirus system, HSV-1,  a rapid loss of killing 
ability has been documented after exposure of CTL,  NK, 
or LAK cells to infected targets (32-35). Direct infection by 
HSV-1 has been proposed as a possible mechanism for such 
functional impairment in CTL and LAK cells (34, 35). How- 
ever, when cell-free HSV-1 was used, the killing ability of 
CTLs was lost only at exceedingly high MOI levels. Cell- 
flee virus inocula were also used in our experiments with 
HHV-6,  but not at similar MOI levels. However, the fact 
that uninfected 3'/8 T  (this report) and NK cells (20)  dis- 
play a significant level of cytotoxic activity in vitro against 
HHV-6-infected targets suggests that HHV-6,  at variance 
with HSV-1, is not able to promptly disarm cytolytic  effectors. 
Further studies are needed to elucidate whether herpesviruses 
exploit common mechanisms for impairing the function of 
antiviral effector cells and thereby elude the immune surveil- 
lance of the host. 
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